Dilt-Cd

Angina Pectoris, Variant, Atrial Fibrillation, Proteinuria + 11 more

Treatment

6 FDA approvals

20 Active Studies for Dilt-Cd

What is Dilt-Cd

Diltiazem

The Generic name of this drug

Treatment Summary

Diltiazem is a medication used to treat high blood pressure, abnormal heart rhythms, and chest pain. It works by blocking the influx of calcium into the cells of the heart and blood vessels, causing them to relax and widen. Diltiazem is available in both oral and intravenous forms and is commonly sold under the brand names Cardizem and Tiazac. It has also been used off-label to treat anal fissures, migraine prevention, pulmonary hypertension, and night-time leg cramps.

Cardizem

is the brand name

image of different drug pills on a surface

Dilt-Cd Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cardizem

Diltiazem

1982

656

Approved as Treatment by the FDA

Diltiazem, commonly known as Cardizem, is approved by the FDA for 6 uses which include Coronary Vasospasm and Coronary Artery Vasospasm .

Coronary Vasospasm

Helps manage Coronary Artery Vasospasm

Coronary Artery Vasospasm

Helps manage Coronary Artery Vasospasm

Anginal Pain

Helps manage Anginal Pain

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Angina Pectoris

Helps manage Anginal Pain

Effectiveness

How Dilt-Cd Affects Patients

Diltiazem is a drug used to treat high blood pressure. It works by relaxing the walls of the blood vessels, which lowers the pressure in the vessels, reducing the risk of strokes and heart attacks. It also reduces heart rate. The amount of blood pressure reduction depends on how high the blood pressure is. Studies on people with essential hypertension have shown that taking diltiazem can reduce diastolic blood pressure by a range of 1.9-8.6 mmHg, depending on the dose taken. People with chronic stable angina have been found to have increased exercise tolerance when taking diltiazem. In a

How Dilt-Cd works in the body

Diltiazem works by blocking calcium channels in the heart and blood vessels, which reduces the amount of calcium entering the cells. This lowers the amount of calcium in the cells, allowing them to relax and reducing tension in the muscle. This leads to dilation of the coronary and systemic arteries, increased oxygen delivery to the heart muscle, decreased total peripheral resistance, decreased blood pressure, and decreased afterload. Diltiazem also decreases heart rate and contractility, making it an effective treatment for chronic stable angina.

When to interrupt dosage

The advocated amount of Dilt-Cd is contingent upon the diagnosed state, including prophylaxis of migraine headaches, Fissure;Anal and Anginal Pain. The dosage is subject to the administration route specified in the table below.

Condition

Dosage

Administration

Angina Pectoris

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Atrial Fibrillation

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Coronary Vasospasm

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Angina Pectoris, Variant

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Proteinuria

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Hypertensive disease

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Angina, Stable

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Tachycardia, Supraventricular

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Cardiomyopathy, Dilated

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Migraine Disorders

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Diabetic Neuropathy

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Pulmonary Hypertension

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Fissure in Ano

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Muscle Cramp

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Injection, solution - Intravenous, Injection, solution, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Solution, Solution - Intravenous

Warnings

Dilt-Cd Contraindications

Condition

Risk Level

Notes

Heart Attack

Do Not Combine

accessory bypass tract

Do Not Combine

accessory bypass tract

Do Not Combine

Bradycardia

Do Not Combine

Ventricular Tachycardia

Do Not Combine

Bradycardia

Do Not Combine

Atrioventricular Block

Do Not Combine

Pulmonary Congestion

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Hypotension

Do Not Combine

There are 20 known major drug interactions with Dilt-Cd.

Common Dilt-Cd Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Diltiazem.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Diltiazem.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Diltiazem.

Alfentanil

Major

The metabolism of Alfentanil can be decreased when combined with Diltiazem.

Amifostine

Major

Diltiazem may increase the hypotensive activities of Amifostine.

Dilt-Cd Toxicity & Overdose Risk

Diltiazem has an oral LD50 ranging from 415 to 740mg/kg in mice and 560 to 810 mg/kg in rats. In dogs, the oral LD50 is estimated to be over 50 mg/kg, and in monkeys it is 360 mg/kg. Reports of overdoses from doses as low as 1g up to 18g have been reported and can cause symptoms such as slow heartbeat, low blood pressure, heart block, or heart failure. Treating an overdose with diltiazem can involve supportive measures, gastric lavage, activated charcoal, and intravenous calcium. Long-term use in animals

image of a doctor in a lab doing drug, clinical research

Dilt-Cd Novel Uses: Which Conditions Have a Clinical Trial Featuring Dilt-Cd?

228 active trials are currently in progress to assess the potential of Dilt-Cd in alleviating Atrial Fibrillation, Coronary Artery Spasm and Paroxysmal Supraventricular Tachycardia (PSVT).

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

95 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Diabetic Neuropathy

5 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pulmonary Hypertension

34 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Tachycardia, Supraventricular

1 Actively Recruiting

Phase 2

Angina, Stable

0 Actively Recruiting

Angina Pectoris, Variant

0 Actively Recruiting

Angina Pectoris

2 Actively Recruiting

Not Applicable, Phase 4

Cardiomyopathy, Dilated

1 Actively Recruiting

Not Applicable

Proteinuria

6 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1, Not Applicable

Muscle Cramp

0 Actively Recruiting

Hypertensive disease

35 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Coronary Vasospasm

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Fissure in Ano

0 Actively Recruiting

Dilt-Cd Reviews: What are patients saying about Dilt-Cd?

4.7

Patient Review

6/20/2008

Dilt-Cd for High Blood Pressure

4.3

Patient Review

6/15/2009

Dilt-Cd for Ventricular Rate Control in Atrial Fibrillation

I felt really dizzy after taking this medication, and it also made me quite depressed. I was in a fog all day long. I think that the dose is way too high for someone who's trying this drug for the first time - 120 mg.

4

Patient Review

5/28/2009

Dilt-Cd for High Blood Pressure

I took this drug for about six weeks and, at first, experienced some adjustments like feeling off-balance. Then I started swelling around my eyes and feeling tightness in my face and chest. Overall, it was an awful experience that led me to the ER where they thought I was having a heart attack. Needless to say, I'll never take another calcium channel blocker!

4

Patient Review

7/31/2009

Dilt-Cd for Ventricular Rate Control in Atrial Fibrillation

My blood pressure was well-controlled on cartia xt, but since switching to dilt cd it has risen back up again. This isn't an effective medication for me.

4

Patient Review

11/29/2009

Dilt-Cd for Hypertrophic Cardiomyopathy

I originally was prescribed 280MG of this medication, but had to reduce my dosage to 180MG because I wheezed so loudly at night that it would wake me up. It was prescribed after I had a pacemaker installed.

3.7

Patient Review

9/22/2009

Dilt-Cd for Ventricular Rate Control in Atrial Fibrillation

Unfortunately, this medication gave me GERD.

3

Patient Review

3/15/2010

Dilt-Cd for Osteoporosis

This treatment is effective. I'm grateful for modern medicine.

2.3

Patient Review

6/5/2009

Dilt-Cd for High Blood Pressure

DILT-CD is the only medication I've taken for high blood pressure that doesn't have any significant side effects. Some downsides are that it can cause pain in my breast and make me urinate more frequently, but overall it's a decent medication.

2

Patient Review

5/15/2009

Dilt-Cd for High Blood Pressure

I've been taking this medication for two decades to keep chest pains at bay and mitigate Reynauld' Syndrome. I take it before bed so that the side effects (which include night sweats) don't bother me while I'm trying to sleep.

2

Patient Review

7/7/2009

Dilt-Cd for High Blood Pressure

I haven't experienced any adverse effects, which is great. The medication has been successful in controlling my atrial fib. I take 120 mg per dose.

1.3

Patient Review

11/8/2007

Dilt-Cd for Ventricular Rate Control in Atrial Fibrillation

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dilt-cd

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is diltiazem CD used for?

"Diltiazem is used to treat high blood pressure and chest pain by relaxing blood vessels and increasing blood and oxygen supply to the heart."

Answered by AI

Is diltiazem ER the same as diltiazem CD?

"Diltiazem is a medication used to treat high blood pressure and prevent chest pain. It works by relaxing blood vessels, which decreases the amount of work your heart has to do. Diltiazem belongs to a group of medications called calcium channel blockers."

Answered by AI

Is diltiazem CD long acting?

"Diltiazem Long-Acting Capsules are used to treat high blood pressure and a type of long-term chest pain known as stable angina."

Answered by AI

What are the side effects of diltiazem CD 120 mg?

"Lightheadedness, dizziness, weakness, nausea, flushing, headache, and constipation may occur. If any of these effects persist or get worse, tell your doctor or pharmacist right away. To lower the risk of dizziness and lightheadedness, get up slowly when going from a sitting or lying down position."

Answered by AI

Clinical Trials for Dilt-Cd

Image of UCSF Medical Center at Parnassus in San Francisco, United States.

Blood Pressure Monitoring for Atrial Fibrillation

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if screening for atrial fibrillation (AFib), a common irregular heart rhythm, through daily home blood pressure monitoring will decrease the time to atrial fibrillation diagnosis in older adults with hypertension. The main question it aims to answer is: \-- Does introducing screening for AFib using a blood pressure monitor with AFib detection technology decrease time to AFib diagnosis in patients with high blood pressure, compared to usual care using a conventional home blood pressure monitor with no AFib detection? Participants will participate in two phases of the study: (1) clinical trial and (2) the registry. During the 6-month clinical trial period, participants will be asked to: * Take blood pressure measurements twice daily * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take blood pressure measurements twice daily * Answer monthly mobile app-based surveys Researchers will compare standard blood pressure measurements and AFib screening blood pressure measurements to see if there is a difference in the time to AFib diagnosis and other cardiovascular events. Participants will participate in two phases of the study: (1) trial and (2) the registry. During the 6-month trial period, participants will be asked to: * Take daily blood pressure measurements * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take daily blood pressure measurements * Answer monthly mobile app-based surveys

Waitlist Available
Has No Placebo

UCSF Medical Center at Parnassus

Gregory M Marcus, MD, MAS

Omron Healthcare Co., Ltd.

Image of Vanderbilt University Medical Center in Nashville, United States.

Nicotinamide Riboside for Pulmonary Hypertension

18 - 85
All Sexes
Nashville, TN

Pulmonary hypertension (PH) is a serious condition that puts strain on the heart and lungs and often leads to frequent hospital stays and shortened life expectancy. The most common cause is heart disease affecting the left side of the heart. A particularly high-risk form, called combined pre- and post-capillary pulmonary hypertension (CPH), occurs in about one in four people with heart failure. There are currently no approved treatments for CPH, and many patients develop right-sided heart failure and die earlier than expected. This study is based on a new approach that uses advanced computer methods to analyze a patient's unique biology and identify potential drug targets. Using this method, we identified nicotinamide riboside (NR) as a promising option for people with CPH. NR is a form of vitamin B3 that helps the body make NAD⁺, a substance essential for how cells produce energy and stay healthy. NAD⁺ plays an important role in how heart and blood vessel cells function. Previous research in animals suggests NR may help improve blood vessel changes in the lungs and support heart function. NR has also shown potential benefits in human studies related to cell energy, mitochondrial health, and reducing oxidative stress. In this study, NR is used only as a dietary supplement that supports normal body processes, not as a proven treatment. The investigators will conduct a small, carefully controlled study in which participants receive NR and a placebo at different times. The goal is to understand how NR affects biological and biochemical markers in the body, not to test whether it improves symptoms or outcomes. Any clinical measurements are included only to help interpret the biological effects.

Recruiting
New This Month

Vanderbilt University Medical Center

Evan L Brittain, MD

Have you considered Dilt-Cd clinical trials?

We made a collection of clinical trials featuring Dilt-Cd, we think they might fit your search criteria.
Go to Trials
Image of Hāmākua-Kohala Health Center in Honokaa, United States.

Produce Prescription for High Blood Pressure

18+
All Sexes
Honokaa, HI

This multi-site randomized controlled trial uses a community-based approach to evaluate a Food as Medicine program for Native Hawaiian and Pacific Islander (NHPI) adults in Hawaii who have high blood pressure and difficulty affording healthy food. The study has two main goals: (1) to implement a produce prescription program and see if adding personal support from Community Health Workers (CHW) improves blood pressure among other health outcomes, and (2) to determine the program's cost-effectiveness. The study will take place across three Federally Qualified Health Centers in Hawaii. Produce prescription program participants at each site will receive $100 per month, either in the form of produce boxes or monthly vouchers to purchase fruits and vegetables, for 12 months (totaling $1200). In past studies, personal challenges (e.g., lack of transportation, lack of cooking skills) have made it difficult for participants to use the vouchers and/or the purchased produce. In other food as medicine interventions, participants have similarly faced various personal, social, and environmental barriers that limit the program's efficacy. To help participants navigate through these challenges, the investigators want to test adding 1-on-1 support from a CHW throughout the program. Other studies have found that health interventions delivered by CHWs have been effective in reducing blood pressure, blood glucose and weight, especially among vulnerable populations, such as NHPIs and those with food insecurity. The CHWs in this study will receive a training using a curriculum tailored specifically to their community and that is in alignment with the Pilinahā: The Four Connections Framework, which focuses on key connections that Indigenous people seek to attain health and can be employed to overcome health disparities. To test the effectiveness of the added CHW support, there will be two groups of participants: Group 1 (Intervention) will receive the monthly produce prescription ($100 vouchers or produce box) plus meet with a CHW every two months for support with program challenges. Group 2 (Control) will receive the same monthly produce prescription, but will not have meetings with a CHW. The investigators want to see if the added support from CHWs leads to better blood pressure results, among other health outcomes. Upon providing informed consent and enrolling into the program, produce prescription program participants will: * Attend 5 study visits over the one year program. These happen at the start, and then at 3, 6, 9, and 12 months. * Complete health checks at the first visit. This includes getting a home blood pressure monitor and learning about heart health and nutrition. Staff will measure height, weight, waist size, and blood pressure. * Answer surveys about their demographic background, health habits, diet, and culture. * Receive $100 in vouchers every month for 12 months to redeem for fruits and vegetables at a local retailer. * Group 1 will additionally meet with a CHW every two months for 1-on-1 support with any challenges related to the program. * Group 2 will receive monthly reminders to use their vouchers but no CHW meetings. After the program ends, researchers will analyze the financial value of the intervention. This involves calculating the total cost to run the program (including vouchers, CHW training and salaries, and administrative costs) and comparing it to potential savings in healthcare costs. By looking at improvements in blood pressure, researchers can estimate how many heart-related health problems were prevented and how much money was saved on medical care.

Waitlist Available
Has No Placebo

Hāmākua-Kohala Health Center (+2 Sites)

Image of Tucson Medical Center in Tucson, United States.

VARIPULSE Catheter for Atrial Fibrillation

18 - 80
All Sexes
Tucson, AZ

The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; PVI and SVCI), with or without another technique called posterior wall isolation (PWI). Also, to assess how safe it is for participants who are having a catheter ablation procedure and at the same time receiving another procedure called left atrial appendage occlusion (LAAO; to reduce stroke risk). Additionally, to assess how well VARIPULSE catheter system works over a long period of time for treatment of PsAF in participants undergoing catheter ablation.

Waitlist Available
Has No Placebo

Tucson Medical Center (+2 Sites)

Biosense Webster, Inc. Clinical Trial

Biosense Webster, Inc.

Have you considered Dilt-Cd clinical trials?

We made a collection of clinical trials featuring Dilt-Cd, we think they might fit your search criteria.
Go to Trials
Image of Montreal Heart Institute in Montreal, Canada.

Dynamic Fluoroscopy for Atrial Fibrillation

18+
All Sexes
Montreal, Canada

Pulsed Field Ablation (PFA) represents a recent advance in the treatment of atrial fibrillation (AF), with a safety profile potentially superior to traditional thermal techniques, such as radiofrequency or cryoablation. Its mechanism of action allows tissue selectivity which in theory limits damage to extracardiac structures. However, several cases of right diaphragmatic paralysis have been reported in the literature after PFA, particularly during applications on the right pulmonary veins, near the right phrenic nerve. The available data are from studies without specific diaphragmatic monitoring. The diagnosis of diaphragmatic paralysis is most often based on chest X-ray, a static examination of limited sensitivity, especially for the detection of incomplete paralysis. To date, no prospective multicentre study has evaluated the incidence of diaphragmatic paralysis after PFA with systematic dynamic imaging, such as fluoroscopy, considered the gold standard for the diagnosis of unilateral paralysis.

Waitlist Available
Has No Placebo

Montreal Heart Institute

Romain TIXIER, MD

Have you considered Dilt-Cd clinical trials?

We made a collection of clinical trials featuring Dilt-Cd, we think they might fit your search criteria.
Go to Trials